Literature DB >> 32909227

Estimating Discounts for Top Spending Drugs in Medicare Part D.

Inmaculada Hernandez1, Alvaro San-Juan-Rodriguez2, Chester B Good3, Walid F Gellad4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32909227      PMCID： PMC8342628          DOI： 10.1007/s11606-020-06194-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   6.473


× No keyword cloud information.
  2 in total

1.  Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.

Authors:  Inmaculada Hernandez; Alvaro San-Juan-Rodriguez; Chester B Good; Walid F Gellad
Journal:  JAMA       Date:  2020-03-03       Impact factor: 56.272

2.  Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.

Authors:  Alvaro San-Juan-Rodriguez; Walid F Gellad; Chester B Good; Inmaculada Hernandez
Journal:  JAMA Netw Open       Date:  2019-12-02
  2 in total
  1 in total

1.  Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.

Authors:  Joshua J Skydel; Alexander C Egilman; Joshua D Wallach; Reshma Ramachandran; Ravi Gupta; Joseph S Ross
Journal:  JAMA Health Forum       Date:  2022-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.